The Concilium of Information Processing Networks of Chemical Oscillators for Determining Drug Response in Patients With Multiple Myeloma
Copyright © 2022 Bose, Dittrich and Gorecki..
It can be expected that medical treatments in the future will be individually tailored for each patient. Here we present a step towards personally addressed drug therapy. We consider multiple myeloma treatment with drugs: bortezomib and dexamethasone. It has been observed that these drugs are effective for some patients and do not help others. We describe a network of chemical oscillators that can help to differentiate between non-responsive and responsive patients. In our numerical simulations, we consider a network of 3 interacting oscillators described with the Oregonator model. The input information is the gene expression value for one of 15 genes measured for patients with multiple myeloma. The single-gene networks optimized on a training set containing outcomes of 239 therapies, 169 using bortezomib and 70 using dexamethasone, show up to 71% accuracy in differentiating between non-responsive and responsive patients. If the results of single-gene networks are combined into the concilium with the majority voting strategy, then the accuracy of predicting the patient's response to the therapy increases to ∼ 85%.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Frontiers in chemistry - 10(2022) vom: 17., Seite 901918 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bose, Ashmita [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Chemical computing |
|---|
| Anmerkungen: |
Date Revised 26.07.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3389/fchem.2022.901918 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM343929562 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM343929562 | ||
| 003 | DE-627 | ||
| 005 | 20231226021604.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3389/fchem.2022.901918 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1146.xml |
| 035 | |a (DE-627)NLM343929562 | ||
| 035 | |a (NLM)35873059 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bose, Ashmita |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Concilium of Information Processing Networks of Chemical Oscillators for Determining Drug Response in Patients With Multiple Myeloma |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.07.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2022 Bose, Dittrich and Gorecki. | ||
| 520 | |a It can be expected that medical treatments in the future will be individually tailored for each patient. Here we present a step towards personally addressed drug therapy. We consider multiple myeloma treatment with drugs: bortezomib and dexamethasone. It has been observed that these drugs are effective for some patients and do not help others. We describe a network of chemical oscillators that can help to differentiate between non-responsive and responsive patients. In our numerical simulations, we consider a network of 3 interacting oscillators described with the Oregonator model. The input information is the gene expression value for one of 15 genes measured for patients with multiple myeloma. The single-gene networks optimized on a training set containing outcomes of 239 therapies, 169 using bortezomib and 70 using dexamethasone, show up to 71% accuracy in differentiating between non-responsive and responsive patients. If the results of single-gene networks are combined into the concilium with the majority voting strategy, then the accuracy of predicting the patient's response to the therapy increases to ∼ 85% | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Oregonator model | |
| 650 | 4 | |a chemical computing | |
| 650 | 4 | |a gene expression values | |
| 650 | 4 | |a genetic optimization | |
| 650 | 4 | |a multiple myeloma | |
| 650 | 4 | |a networks | |
| 650 | 4 | |a oscillations | |
| 700 | 1 | |a Dittrich, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Gorecki, Jerzy |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Frontiers in chemistry |d 2013 |g 10(2022) vom: 17., Seite 901918 |w (DE-627)NLM237900548 |x 2296-2646 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2022 |g day:17 |g pages:901918 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3389/fchem.2022.901918 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2022 |b 17 |h 901918 | ||